BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $8.80, but acceptable to hold if already in. Reason: Negative momentum.
BioCryst Pharmaceuticals is a global biotechnology company commercializing ORLADEYO (berotralstat), an oral once-daily HAE prevention therapy approved in the U.S. and multiple international markets. Following the January 2026 acquisition of Astria Therapeutics, BioCryst also... Read more
Hold if already holding. Not a fresh buy at $8.80, but acceptable to hold if already in. Reason: Negative momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 76d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — BioCryst Pharmaceuticals, Inc.
Latest news
- Nasdaq, S&P 500 futures rise ahead of PMI data, Iran tensions cap risk appetite: Why NVDA, GME, AAOI, BCRX are keeping t — MSN neutral
- BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Wednesday - MarketBeat — MarketBeat neutral
- BioCryst gains amid takeover speculation - MSN — MSN positive
- BCRX Jumps As Price Target Hike Caps Busy Catalyst Week - StocksToTrade — StocksToTrade positive
- BioCryst Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:BCRX) 2026-05-06 - Seeking Alpha — Seeking Alpha neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $8.80, but acceptable to hold if already in. Reason: Negative momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $18.53 (+110.6%), stop $8.16 (−7.8%), A.R:R 10.0:1. Score 6.1/10, moderate confidence.
Take-profit target: $18.53 (+111.3% upside). Target $18.53 (+110.6%), stop $8.16 (−7.8%), A.R:R 10.0:1. Stop-loss: $8.16.
Negative momentum.
BioCryst Pharmaceuticals, Inc. trades at a P/E of N/A (forward 13.2). TrendMatrix value score: 8.5/10. Verdict: Hold.
16 analysts cover BCRX with a consensus score of 4.3/5. Average price target: $21.
What does BioCryst Pharmaceuticals, Inc. do?BioCryst Pharmaceuticals is a global biotechnology company commercializing ORLADEYO (berotralstat), an oral once-daily...
BioCryst Pharmaceuticals is a global biotechnology company commercializing ORLADEYO (berotralstat), an oral once-daily HAE prevention therapy approved in the U.S. and multiple international markets. Following the January 2026 acquisition of Astria Therapeutics, BioCryst also holds navenibart (Phase 3 injectable HAE therapy) and early-stage programs in Netherton syndrome and DME. Commercial rights for Europe are held by Neopharmed (sold October 2025) and Japan by Torii.